Abstract
We studied 76 patients with endocrinological features of prolactin-secreting microademnoma by MRI, using three dimensional (3D) gradient echo acquisition (FLASH) sequences. MRI revealed a focal signal abnormality in the pituitary in all 37 patients who had not previously taken bromocriptine. However, focal abnormality was shown in only half the patients had been on dopamine agonist therapy; the MRI findings in these 39 patients were not affected by the duration and dosage bromocriptine, nor by the time elapsed since its discontinuation. The microadenoma gave spontaneous high signal on the unenhanced T1-weighted images in 8 cases; it was not seen on unenhanced images in 25 cases. It appeared as low signal within the enhancing gland in 51 cases but enhanced in 7 cases. The 3D technique gives thin (1 mm) slices and therefore facilitates detection of small focal abnormalities in the pituitary gland (2×2 mm). In the 19 previously treated patients in whom MRI did not demonstrate a focal abnormality, it showed localised atrophy of the gland in 3, a large, round gland with homogeneous signal in 1, and a heterogeneous appearance in 11; it was normal in 4 cases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bonneville JF, Cattin F, Dietemann JL (1986) Computed tomography of the pituitary gland. Springer, Berlin Heidelberg New York, pp 63–88
Bilaniuk LT, Zimmerman RA, Wehrli FW, Snyder PJ, Goldberg HJ, Grossman RI, Bottomley PA, Edelstein WA, Glover GH, Macfall JR, Redington RW (1984) Magnetic resonance imaging of pituitary lesions using 1.0 to 1.5 T field strength. Radiology 153: 415–418
Davis PC, Gokhale KA, Joseph GJ, Peterman SB, Adams DA, Tindall GT, Hudgins PA, Hoffman JC Jr (1991) Pituitary adenoma: correlation of half-dose gadolinium-enhanced MR imaging with surgical findings in 26 patients. Radiology 180: 779–784
Kucharczyk W, Davis DO, Kelly WM, Sze G, Norman D, Newton TH (1986) Pituitary adenomas: high resolution MR imaging at 1.5 T. Radiology 161: 761–765
Kulkani MV, Lee KF, McArdle CB, Yeakley JW, Haar FZ (1988) 1.5 T MR imaging of pituitary microadenomas: technical considerations and CT correlation. AJNR 9: 5–11
Nichols DA, Laws ER, Houser OW, Abboud CF (1988) Comparison of magnetic resonance imaging and computed tomography in the preoperative evaluation of pituitary adenomas. Neurosurgery 22: 380–385
Pojunas KW, Daniels DL, Williams A, Haughton VM (1986) MR imaging of prolactin-secreting microadenomas. AJNR 7: 209–213
Stadnik T, Stevenaert A, Beckers A, Luypaert R, Buisseret T, Osteaux M (1990) Pituitary microadenoams: diagnosis with two and three dimensional MR imaging at 1.5 T before and after injection of gadolinium. Radiology 176: 419–428
Girard N, Cortesi L, Chabert-Orsini V, Maman P, Brue T, Jaquet P, Raybaud C (1992) Three dimensional magnetic resonance imaging of prolactin-secreting microadenomas. Ann Endocrinol (Paris) 53: 8–15
Johnson MR, Hoare RD, Cox T, Dawson M, MacCabe JJ, Llewellyn H, McGregor AM (1992) The evaluation of patients with a suspected pituitary microadenoma: computer tomography compared to magnetic resonance imaging. Clin Endocrinol 36: 335–338
Elster AD (1993) Sellar susceptibility artifacts: theory and implications. AJNR 14: 129–136
Davis PC, Hoffman JC, Spencer T, Tindall GT, Braun JF (1987) MR imaging of pituitary adenoma: CT, clinical, and surgical correlation. AJR 148: 797–802
Gorczyca W, Hardy J (1988) Microadenomas of the human pituitary and their vascularization. Neurosurgery 22: 1–6
Schechter J, Goldsmith P, Wilson C, Weiner R (1988) Morphological evidence for the presence of arteries in human prolactinomas. J Clin Endocrinol Metab 67: 713–717
Miki Y, Matsuo M, Nishizawa S, Kuroda Y, Keyaki A, Makita Y, Kawamura J (1990) Pituitary adenomas and normal pituitary tissue: enhancement patterns on gadopentate-enhanced MR imaging. Radiology 177: 35–38
Hassoun J, Jaquet P, Devictor B, Andonian C, Grisoli F, Gunz G, Toga M (1985) Bromocriptine effects on cultured human prolactin-producing pituitary adenomas: in vivo ultrastructural, morphometric, and immunoelectron microscopic studies. J Clin Endocrinol Metab 1: 686–692
Landolt AM, Osterwalder V (1984) Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? J Clin Endocrinol Metab 58: 1179–1183
Perrin G, Treluyer C, Trouillas J, Sassolas G, Goutelle A (1991) Surgical outcome and pathological effects of bromocriptine preoperative treatment in prolactinomas. Path Res Pract 187: 587–592
Yousem DM, Arrington JA, Zinreich SJ, Kumar AJ, Bryan RN (1989) Pituitary adenomas: possible role of bromocriptine in intra-tumoral hemorrhage. Radiology 170: 239–243
Tindall GT, Kovacs K, Horvath E, Thorner MO (1982) Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 55: 1178–1183
Weissbuch SS (1985) Explanation and implications of MR signal changes within pituitary adenomas after bromocriptine therapy. AJNR 7: 214–216
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Girard, N., Brue, T., Chabert-Orsini, V. et al. 3D-FT thin sections MRI of prolactin-secreting pituitary microadenomas. Neuroradiology 36, 376–379 (1994). https://doi.org/10.1007/BF00612122
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00612122